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The predominant population of γδ T cells in human blood express a T cell receptor (TCR)
composed of a Vγ9 (Vγ2 in an alternate nomenclature) and Vδ2 domains.These cells came
into the limelight when it was discovered they can respond to certain microbial infections
and tumorigenic cells through the detection of small, pyrophosphate containing organic
molecules collectively called “phosphoantigens” or “pAgs.”These molecules are interme-
diates in both eukaryotic and prokaryotic metabolic pathways. Chemical variants of these
intermediates have been used in the clinic to treat a range of different cancers, however,
directed optimization of these molecules requires a full understanding of their mechanism
of action on target cells. We and others have identified a subclass of butyrophilin-related
molecules (BTN3A1-3) that are directly involved in pAg sensing in the target cell, leading
to engagement and activation of the T cell through the TCR. Our data and that of others
support the pAg binding site to be the intracellular B30.2 domain of BTN3A1, which is
the only isoform capable of mediating pAg-dependent stimulation of Vγ9Vδ2 T cells. Here,
we review the data demonstrating pAg binding to the B30.2 domain and our studies of
the structural conformations of the BTN3A extracellular domains. Finally, we synthesize a
model linking binding of pAg to the intracellular domain with T cell detection via the extra-
cellular domains in an “inside-out” signaling mechanism of the type characterized first for
integrin molecule signaling. We also explore the role of Vγ9Vδ2TCR variability in the CDR3
γ and δ loops and how this may modulate Vγ9Vδ2 cells as a population in surveillance of
human health and disease.
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Gamma delta T cells represent a conundrum when trying to under-
stand the mechanisms of T cell ligand recognition that results in
T cell activation. T cells expressing αβ T cell receptors (TCRs) that
develop normally in the thymus recognize all antigens with the
requirement of an antigen-presenting molecule belonging to the
MHC superfamily. This MHC requirement encompasses conven-
tional αβ T cell recognition of classical class I and class II MHC
molecules as well as innate-like or semi-invariant T cell recogni-
tion of non-classical or MHC-like molecules. Examples include
Type I invariant Natural Killer T (iNKT) and Type 2 NKT cell
recognition of CD1d, Mucosal Associated Invariant T (MAIT) cell
recognition of MR1, and non-conventional αβ T cell recognition
of the human Group 1 CD1s (1). While these different T cell types
recognize their various MHC ligands with diverse footprints, the
fact remains that they are all “restricted” to recognizing antigens
in the context of their respective MHCs.
This same MHC requirement does not appear to hold true
for γδ T cells. While defining ubiquitous antigens for this lin-
eage of T cells have been challenging, a clearer perspective has
started to emerge with recent breakthroughs in antigen definition
for these cells. While a comprehensive survey of these results is
not the focus of this review and has been discussed elsewhere (2,
3), what has emerged from these studies is that γδ T cell are spe-
cific for both MHC and non-MHC proteins. To first understand
this conundrum it is important to emphasize that γδ T cells
cannot be grouped together as a whole. Instead, γδ T cells are
divided into many different populations with different antigen
reactivities, effector functions, and tissue residence (4, 5). Another
important point is that there is little, if any, homology between
γδ T cell populations in mice with those in humans, suggesting
that these cells have rapidly adapted to different antigenic stim-
uli or immunological environments in the two different hosts.
This is supported by the observed rapid evolution of many of
the Vγ genes within the primate lineage (6, 7). Recent work
from our laboratory has focused on two very different γδ T
cell populations in humans: first, those that do recognize anti-
gens in the context of CD1 molecules, which has been reviewed
elsewhere (8); and secondly a population that appears to be MHC-
independent and instead responds to small pyrophosphate anti-
gens called “phosphoantigens (pAgs)”. This second population,
called “Vγ9Vδ2”, “Vγ2Vδ2”, or “γ2δ2” by different groups, called
Vγ9Vδ2 here, is the topic of this review. Recent breakthroughs
by several groups have started to reveal the complex mechanism
behind pAg regulation of this cell population. These findings have
led to a shift in the paradigm of what specificities regulate T
cell activity and a better understanding of the molecular mech-
anisms behind regulation of this important T cell population in
humans.
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Vγ9Vδ2 T cells are the major subset of γδ T cells found in
human blood, comprising up to 5% of the T cells in healthy
individuals and expanding to 20–50% during infection or dis-
ease (9). These cells play important roles in mediating immunity
against microbial pathogens, including Mycobacterium tuberculo-
sis and Mycobacterium leprae [the causative agents of tuberculosis
and leprosy, respectively, reviewed in Ref. (10)], and can respond
potently against certain types of tumor cells (11, 12). No homol-
ogous pAg-reactive Vγ9Vδ2 T cell population has been identified
in rodents or lagomorphs, however, genes homologous to both
Vδ2 and Vγ9 have been identified in other placental mammalian
species including sloth, armadillo, lemur, aye aye, bottlenose dol-
phin, killer whales, and horse (13). Furthermore, expression of
Vγ9Vδ2 TCRs was demonstrated in alpacas. This suggests that
Vγ9Vδ2 T cells are present in species outside the primate lineage
and likely predate the split of the placental mammals. The lack
of Vγ9Vδ2 T cells in rodents and lagomorphs demonstrate that
this lineage has been lost in some species, perhaps compensated
by selection for alternative T cell subtypes.
As mentioned above, Vγ9Vδ2 T cells represent an important
departure from the classical T cell recognition paradigm, in that no
MHC or MHC-like molecules have been implicated in their activa-
tion (14). Instead, the aforementioned pAgs (Figure 1), which are
pyrophosphate containing metabolites, are the key trigger (15–
18). Amongst these, isopentenyl pyrophosphate (IPP) (16, 19)
is generated from the endogenous mevalonate (MVA) pathway
(HMG-CoA, cholesterol biosynthesis) and accumulates intracel-
lularly during dysregulated metabolism in many types of tumor
cells. Addition of aminobisphosphonates like zoledronate (NBP)
or alkylamines also causes intracellular IPP accumulation through
inhibition of farnesyl pyrophosphate synthase (12, 20, 21); this
strategy is used frequently in studies of Vγ9Vδ2 T cell stimula-
tion. A much more potent set of pAgs (i.e., HDMAPP/HMBPP:
hydroxy-methyl-butyl-pyrophosphate) are microbial metabolites
from the isoprenoid pathway (17) and represents “non-self”
pathogen signals. A synthetic pAg, bromohydrin pyrophosphate
(BrHPP) also strongly activates Vγ9Vδ2 T cells and is often used
in in vitro functional experiments (22). The pAg-induced recogni-
tion of target cells is TCR dependent, as Vγ9Vδ2 TCR transfected
Jurkat cells become activated by pAgs (23). While no direct inter-
action has been detected between pAgs and the γδTCR, cell-to-cell
contact is necessary in pAg-induced γδ T cell activation (14, 24),
indicating that molecules expressed on the cell-surface of target
cells or γδ T cells are required for activation.
FOCUS ON BUTYROPHILINS AS KEY PLAYERS IN THE Vγ9Vδ2
T CELL RESPONSE TO pAgs
A major breakthrough in our understanding of Vγ9Vδ2 T cell acti-
vation came with the identification of the butyrophilin-3 (BTN3)
protein family as a key mediator in this process (25). BTN3 pro-
teins,also known as CD277,are type I membrane proteins with two
immunoglobulin (Ig)-like extracellular domains (IgV and IgC)
(26, 27) (Figure 2A) with close structural homology to the B7-
superfamily of proteins. BTN3A molecules are members of a much
larger butyrophilin superfamily with diverse roles in host home-
ostasis (28, 29). A key factor in the initial discovery of the role of
BTN3A in Vγ9Vδ2 activation was the serendipitous discovery that
FIGURE 1 | Examples of phosphoantigens (pAgs) that stimulate
Vγ9Vδ2T cells. Phosphoantigens (pAgs) that derive from the mevalonate
pathway (“endogenous” IPP and synthetic derivative EtPP) are circled in
blue whereas those that produced in the isoprenoid pathway of microbes
(“exogenous” HDMAPP or synthetic derivative cHDMAPP) are circled in
pink. The pyrophosphate motif is highlighted in pink; the chemically diverse
organic moieties are shown as lines.
a mouse antibody (clone 20.1), raised against human BTN3A mol-
ecules, caused a surprising proliferation and expansion of γδT cells
in IL-2 supplemented peripheral blood mononuclear cell (PBMC)
cultures (25). The presence of this antibody elicited production of
IFN-γ, TNF-α, and upregulation of the activation marker CD69
and has recently been shown to elicit very similar intracellular
signaling in Vγ9Vδ2 T cells as pAgs (30). This phenomenon was
restricted to the Vγ9Vδ2 population in PBMCs, with no effect on
αβ T cells or those γδs not expressing a Vγ9Vδ2 TCR. Consistent
with the lack of MHC requirement for stimulation of this γδ T
cell population, addition of the 20.1 antibody to a panel of human
tumor/transformed cell lines, some of which lack MHC surface
expression, induced potent activation of responding Vγ9Vδ2 T
cells (25). To rule out an effect of BTN3A expressed on Vγ9Vδ2
T cells, murine Vγ9Vδ2 TCR transductants, which do not express
BTN3A molecules, were used as effector cells and shown to also
respond to these 20.1 treated target cells. This experiment also con-
firms the requirement for the Vγ9Vδ2 TCR, supporting previous
studies in Vγ9Vδ2 Jurkat transfectants (23). Similar results with
the 20.1 Ab were found by another group (31). Other approaches
also confirmed the role of BTN3A molecules in Vγ9Vδ2 T cell acti-
vation; taking a genetic approach, Vavassori et al. mapped genetic
elements required forVγ9Vδ2 T cell activation to the 3- to 27.4-Mb
interval of human chromosome 6 and further refined their candi-
dates by screening only those coding regions that had a predicted
transmembrane element (32). Included within these candidates
were the BTN3A molecules.
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FIGURE 2 | Domain organization of the butryophilin-3 (BTN3) proteins.
(A)The BTN3A extracellular domains are members of the B7-superfamily
with a membrane-proximal IgC domain and an N-terminal IgV domain. The
extracellular domains between the three isoforms are highly similar, but are
linked, via a single-pass transmembrane region, to intracellular domains
that vary amongst the three BTN3A family members. BTN3A1 and BTN3A3
both contain intracellular B30.2 domains whereas BTN3A2 does not.
BTN3A1, circled with a dotted line, has been shown to be necessary for
pAg-induced activation of Vγ9Vδ2 T cells. (B)The three-dimensional
structures of the extracellular domain of BTN3A1 is shown in cyan (left) and
superimposed with the A2 and A3 isoforms (right) shown in gold and pink,
respectively. The structures are highly homologous, with only small
variations in the hinge angles between the IgV and Ig-C domains.
Three isoforms of BTN3A are present in humans, BTN3A1,
BTN3A2, and BTN3A3, each encoded by a separate gene (26). The
extracellular domains of the BTN3A molecules are highly sequence
and structurally homologous, with only minor variations observed
in the hinge angle between the IgV and IgC domains of their crys-
tal structures when the three extracellular domain structures are
superimposed (27) (Figure 2B). All three BTN3A isoforms are rec-
ognized by the 20.1 antibody and can mediate 20.1 mAb-induced
activation of Vγ9Vδ2 T cells (25, 27), suggesting that a shared epi-
tope on BTN3A molecules is involved in the process of Vγ9Vδ2
stimulation. Curiously, a different BTN3A specific antibody, 103.2,
had an antagonistic effect on pAg-mediated Vγ9Vδ2 stimulation
after addition to target cells, suggesting that it either blocks an epi-
tope on the BTN3A extracellular domain or induces or stabilizes a
non-stimulatory conformation of BTN3A on the cell-surface (25).
In the crystal structures of the BTN3A extracellular domains,
two dimeric interfaces were observed (27), one that would gener-
ate a symmetric V-shaped homodimer positioning the C-terminal
transmembrane domains close together (Dimer 1, Figure 3) and
the other a head-to-tail homodimer with an asymmetric dimer
interface, requiring the BTN3A molecules to lay flat, parallel to
the cell-surface (Dimer 2, Figure 3). Both dimer interfaces were
of appreciable size, Dimer 1 buried ∼1520 Å2 whereas Dimer 2
buried ∼1080 Å2. Both dimer interfaces were also highly con-
served between the three BTN3A isoforms; only 2 out of the
18 interface residues in Dimer 2 differed between the BTN3A
isoforms. However, the Dimer 2 interface was observed in the
crystal structures of all three BTN3A isoforms indicating these
FIGURE 3 | Cartoon representation of the domain organization of the
butryophilin-3 (BTN3) proteins. Structures of the extracellular domains of
the BTN3A1 proteins shown in the two dimeric states present in the crystal
lattice. Dimer 1 (left) associates via the IgC domains and forms a V-shaped
dimer, placing the intracellular B30.2 domains in close proximity to each
other. Dimer 2 (right) associates in an head-to-tail fashion with the IgV
domain of one BTN3A monomer interacting with the IgC domain of
another. This would result in the dimer laying parallel to the cell-surface,
with the intracellular B30.2 domains separated. The interface contact
residues are colored pink and shown on the surface representation of the
two dimeric forms (middle panel). The buried surface area (BSA) is shown
for both dimers.
differences were tolerated. Residues involved in the Dimer 1 inter-
face differed at three positions across the three BTN3A isoforms
although examination of the contacts in this interface revealed that
these interactions involved only main chain atoms, thus tolerat-
ing variation in the composition of the side chain residues. This
suggests that these extracellular domains can form heterodimers
adopting both dimeric conformations when co-expressed on the
cell-surface. Using soluble extracellular domains, we were able to
establish that BTN3A molecules exist as stable homodimers in
solution and, using a FRET approach, that the dimer conformation
in solution was Dimer 1 (27). This does not, however, rule out the
possibility that both dimers can exist on the cell-surface, perhaps
stabilized through the transmembrane or intracellular domains
not present in the soluble molecules.
Insight into the binding sites and mode of action of the 20.1
and 103.2 antibodies was revealed with the complex crystal struc-
tures of single-chain versions of these antibodies (containing just
the antigen-binding V domains) in complex with BTN3A1 (27).
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FIGURE 4 | Model of the regulation of BTN3A architecture by the
agonist 20.1 and antagonist 103.2 antibodies. Structures of the
extracellular domains of the BTN3A proteins (cyan) in complex with
agonist (20.1, green) and antagonist (103.2, red) antibody single chains
(scFv). The 20.1 antibody cannot “reach” across a BTN3A dimer 1 to
occupy both binding sites and therefore is likely to multimerize BTN3A
molecules on the cell-surface (left). The 20.1 antibody binds to the Dimer
2 interface of the IgV domain and therefore would disrupt the Dimer 2
conformation on the cell-surface.The 103.2 antibody can bind both Dimer
1 and Dimer 2 conformations, either potentially blocking the activating
Dimer 1 form or stabilizing the “inactive” Dimer 2 form on the
cell-surface.
These complex structures demonstrated that these two antibod-
ies bind to separate epitopes on the BTN3A surface (Figure 4),
a result confirmed by competition-binding assays performed by
Surface Plasmon Resonance (SPR). Curiously, the 20.1 antibody
binding site positions the antibody such that it cannot bind biva-
lently to one BTN3A dimer as the two binding sites are too distant.
For both 20.1 antibody binding sites to be occupied in the Dimer 1
conformation would require engagement of two separate BTN3A
homodimers. Thus, binding of the 20.1 antibody could effectively
cross-link these molecules on the cell-surface. Also interesting was
the finding that the 20.1 binding site overlaps with that of the
Dimer 2 interface, suggesting that binding of the 20.1 antibody
would compete with the Dimer 2 conformation (Figure 4) and
instead select for, and stabilize, the Dimer 1 conformation. The
103.2 epitope is accessible in both Dimer 1 and Dimer 2 confor-
mations; in contrast to the 20.1 antibody, 103.2 would likely bind
with both binding sites to one BTN3A Dimer 1, but would have to
cross-link BTN3A molecules in the Dimer 2 conformation.
These results lead us to propose a model whereby these two
dimeric states are related to the stimulatory potential of the
cell upon which they are expressed. In normal, non-stimulatory
conditions, BTN3A molecules would exist in the Dimer 2 state
(head-to-tail) and thus not be in a state to provide a stimulatory
signal to surveying Vγ9Vδ2 T cells. Upon addition of the 20.1
antibody, BTN3A molecules in the Dimer 2 conformation would
be converted to Dimer 1; these would be cross-linked on the cell-
surface via binding of one 20.1 antibody to two BTN3A dimers,
and thus be converted into a “stimulatory” conformation permis-
sible to stimulate Vγ9Vδ2 cells (Figure 4). The potential ability of
the 20.1 antibody to cross-link BTN3A molecules in this model
is consistent with the observed immobilization of BTN3A mole-
cules via Flourescence Recovery after Photobleaching (FRAP) that
occurs during conversion of a cell from a non-stimulatory to stim-
ulatory state (25). This model also proposes that addition of 103.2
antibody could either block a site on BTN3A required for Vγ9Vδ2
cells activation or stabilize the Dimer 2 conformation on the cell-
surface (Figure 4), thus leading to the inhibitory activity observed
when this antibody is added in conjunction with pAg.
But what is the role of pAg in this process? Failed efforts to
show a direct interaction between the Vγ9Vδ2 TCR and pAg early
on suggested additional players were involved in this process; the
requirement of cell–cell contact for Vγ9Vδ2 T cell stimulation
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also supported this hypothesis (14). Based on recent published
results, two general models have been proposed to explain how pAg
functions to stimulate Vγ9Vδ2 T cells. The first model is tantaliz-
ingly simple; it describes the extracellular domain of BTN3A mole-
cules as “antigen-presenting” whereby BTN3A molecules associate
with pAg and “present” it directly to the Vγ9Vδ2 TCR (32). While
this model would fit well with the requirement of an antigen-
presenting molecule for αβ T cell recognition of antigen, this
model has met with controversy and is not supported by data gen-
erated from several groups and discussed further below. Model
2 is based on the finding that only one of the three BTN3A iso-
forms (BTN3A1) can support pAg-mediated Vγ9Vδ2 activation.
This was demonstrated through siRNA knock-down experiments
and reintroduction of individual BTN3A1, BTN3A2, or BTN3A3
isoforms; BTN3A1 alone was found to be pAg-reactive (25). This
suggests that there is a unique element to this isoform that alone
can initiate stimulation in a pAg specific way. Domain deletion
and swapping experiments gave the first indication of the identity
of this unique element: BTN3A1 lacking its intracellular domain
failed to mediate pAg-mediated Vγ9Vδ2 stimulation but was
highly stimulatory upon addition of the 20.1 antibody. BTN3A3,
which cannot support pAg-mediated stimulation of Vγ9Vδ2 T
cells, was made pAg stimulatory by swapping of its intracellular
domain with that of A1 (31, 33). These data strongly support a
pivotal role of the intracellular domain of the BTN3A1 isoform
in pAg-mediated Vγ9Vδ2 stimulation. Model 2 is based on these
findings and focuses on the intracellular domain of BTN3A1 as
the pAg sensor.
The three BTN3A molecules differ substantially in their intra-
cellular domains; A1 and A3 each contain a B30.2 domain
(also known as PRY/SPRY domains) whereas A2 lacks this domain
(Figure 2). The B30.2 domains found in A1 and A3 are highly
homologous, with 87% amino acid identity between the two
(Figure 5). The intracellular region of A3, however, has a unique
70 amino acid extension C-terminal to its B30.2 domain (Figures 2
and 5). B30.2 domains are classified as protein–protein interaction
domains and are found in other butyrophilin family members as
well as non-related proteins (over 50 genes in the human genome
have predicted B30.2 domains). Many B30.2 domain-containing
proteins have been reported to be important in immune func-
tion, including the TRIM and pyrin families (34), although in
most cases the binding partners have not been characterized. The
importance of the B30.2 domain in pAg sensing was first demon-
strated through swapping of just this domain between the A1
(capable of pAg activation) and A3 (incapable of activation) iso-
forms (33). Introduction of the A1 B30.2 domain into the A3
isoform converted this isoform to stimulatory for Vγ9Vδ2 T cell
in the presence of pAg, whereas, the reverse swap (A3-B30.2 into
A1 isoform) abrogated its ability to stimulate Vγ9Vδ2 T cells in a
pAg-dependent fashion.
INTRACELLULAR B30.2 DOMAIN OF BTN3A1 AS THE pAg
SENSOR
Direct interactions between both endogenous and exogenous
pAgs with the B30.2 domain of BTN3A1 were measured with a
highly sensitive technique called Isothermal Titration Calorime-
try (ITC), which measures the heat absorbed or lost during
binding events (33, 35). The affinities calculated from these tech-
niques (KD=∼1µM for exogenous pAg,∼1mM for endogenous
pAg) also reflected the functional potency of these compounds
FIGURE 5 | Alignment of the intracellular B30.2 domains from BTN3A1
and BTN3A3. Amino acids are shown in the single letter designations,
BTN3A1 is the consensus. “-” indicates positions of identity with BTN3A1,
differences are shown in their single letter abbreviations. Green boxes
indicate residues within 5 Å of the phosphoantigen binding pocket. BTN3A3
has an additional polypeptide extension.
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FIGURE 6 | Structure of the intracellular B30.2 domain of BTN3A1.
Shown is a cartoon diagram of the B30.2 domain dimer identified in the
crystal lattice. Monomer 1 is shown in yellow, monomer 2 in green. N- and
C-termini are shown as blue and red spheres, respectively, as is the
putative orientation of these molecules in relation to the cell membrane.
Turning monomer 1 approximately 90° and generating an electrostatic
representation of the B30.2 surface, a highly positively charged pocket is
clear (indicated by the dashed yellow box).
in mediating stimulation of Vγ9Vδ2 T cells. The endogenous
IPP pAg is typically 1,000-fold weaker potency than that of the
exogenous HMBPP (36). Association studies with the HMBPP
pAg were also shown via chemical shift perturbations (CSP) via
Nuclear Magnetic Resonance (NMR), an equally sensitive tech-
nique (35). Of note, no association of pAgs could be measured
with the BTN3A3-B30.2 domain, or to the extracellular domains
of BTN3A1, A2 or A3, with either of these techniques (33, 35).
The crystal structure of the B30.2 domain of BTN3A1
(Figure 6) was highly informative in deciphering the pAg bind-
ing site (33). The structure of BTN3A1 B30.2 domain was highly
homologous to previously reported B30.2 domains, in particular
the B30.2 domain of Trim21, an intracellular Fc receptor (37).
Importantly, specific to the BTN3A1 B30.2 domain was a highly
positively-charged (basic) pocket nestled in Sheet A of the struc-
ture (Figure 6). This pocket was lined with basic residues including
arginines (R412,R418,and R469),histidines (H351 and H378) and
a lysine (K393) (Figure 7). The charge complementarity between
the B30.2 positively charged pocket and the negative charge of
pAgs made this an excellent candidate for pAg binding.
Charge swapping mutagenesis studies, where the basic residues
were mutated to acidic (negatively charged), completely abrogated
pAg binding and reactivity in cell stimulation assays, providing
compelling evidence that this indeed was the pAg binding pocket
(33). However, these results did not explain entirely the differ-
ences of pAg binding to the A1 versus A3-B30.2 domains. Close
FIGURE 7 | Phosphoantigen binding pocket of B30.2 domain. Close-up
view of the B30.2 pAg binding pocket with the side chains lining the pocket
shown under the semi-transparent surface. The positions are labeled with
the numbering relative to the full-length BTN3A1 molecule. The pAg is
shown as sticks, modeled into the binding pocket; phosphates are colored
orange and red (oxygen) and the organic moiety is shown in yellow.
examination of the amino acid differences between these isoforms
revealed a single amino acid difference that lay within the bind-
ing pocket: position 351 was a histidine in A1 and an arginine
in A3 (Figure 5). Swapping of this single amino acid difference
between the domains (i.e., mutating the H to R in A1 and R to H
in A3) transferred both pAg binding ability and functional ability
to stimulate Vγ9Vδ2 T cells. Position 351 is quite buried within
the pAg binding pocket; it is likely that the size and shape of the
side chain difference from an H to an R changes the architecture of
the binding pocket such the pAgs thus characterized do not bind
to A3. This raises the possibility that there are other pyrophos-
phate compounds yet to be described that may preferentially bind
to A3 over A1. It is unclear as to the role, if any, of the A2 and
A3 isoforms in Vγ9Vδ2 T cell activation; their potential ability to
form heterodimers with A1, assemble with alternative antigens via
their B30.2 domain (in the case of A3) and modulate cell-surface
assembly with other protein binding partners is an area of active
investigation.
Additional insight into the mechanics of pAg binding to
the B30.2 domain, pursued through crystallization and NMR
experiments, have revealed evidence for a conformational change
induced in the B30.2 domain upon pAg binding. The first insight
into this was during our pursuit of a complex structure between
the B30.2 domain and pAg where we attempted to “soak” pAg
into already existing crystals (33). (This is a common approach
for studying small molecule binding sites in proteins.) While pro-
tein crystals appear solid, they contain a substantial amount of
liquid that forms solvent channels between the protein molecules.
Thus, small molecules (such as pAgs) can move freely in the crys-
tal lattice and bind to their appropriate binding site in the protein
as it is locked in the crystal lattice. This methodology assumes
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that binding of the small molecule does not induce changes in
the conformation of the protein as this can disrupt the packing of
the protein in the crystal lattice and cause the crystals to dissolve.
Soaking of B30.2 domain crystals with pAgs did just this, caus-
ing the crystals to dissolve immediately upon addition. Locking
of the protein–protein contacts within the crystal lattice via cova-
lent crosslinking via glutaraldehyde preserved the crystal structure
and allowed a complex structure of pAg and B30.2 to be resolved.
Within this structure there is clear tetrahedral electron density
for the beta- and alpha- phosphates of the pAg within the bind-
ing pocket, however, the organic portion of the pAg could not be
resolved (33). More direct evidence for a conformational change is
seen in CSP observed in the Heteronuclear single quantum coher-
ence spectroscopy (HSQC) of apo (empty) B30.2 versus that with
added HMBPP (35). Thus, it is clear that binding of pAg to the
B30.2 domain induces structural rearrangements/conformational
changes that we hypothesize is the first in a cascade of intracellu-
lar and extracellular events leading to target cell transmission of a
stimulatory signal to the Vγ9Vδ2 TCR.
This model of intracellular sensing of pAgs is consistent with
the fact that many of the physiologically relevant pAgs are first
generated and accumulate inside target cells. Endogenous pAgs,
such as IPP or DMAPP, are intermediates of the MVA path-
way, which is conserved in eukaryotes and archaea for isoprenoid
biosynthesis (38). It has been reported that these pAgs accumulate
intracellularly during dysregulated metabolism in many types of
human tumor cells. For example, overexpression of HMG-CoA
reductase, the rate limiting enzyme of the MVA pathway, in the
non-Hodgkin B cell lymphoma cell-line Daudi and mammary
cancer cells such as breast adenocarcinoma cells, can cause an
increased level of IPP that is then recognized by Vγ9Vδ2 T cells
(12, 39). Manipulation of the MVA pathway by various synthetic
drugs (such as statins and aminobisphosphates) or short hairpin
RNAs targeted to enzymes either upstream or downstream of IPP
production can trigger or suppress pAg-induced T cell activation,
supporting the idea that Vγ9Vδ2 T cells can sense intracellular
IPP levels (12, 20, 21, 40). Another set of pAgs derive from exoge-
nous microbial sources and are also much more potent. These
metabolites, such as HMBPP from the microbial methylerythritol
phosphate (MEP) pathway, exist in bacteria and several photosyn-
thetic eukaryotes (38). Some microbes producing these pAgs are
intracellular pathogens such as Mycobacterium tuberculosis and
Listeria monocytogenes, which can enter and survive within the
host cells (41, 42). Immune cells such as monocytes, macrophages
and dendritic cells can also engulf these pathogens and elicit pAg-
dependent T cell responses (43–46). Extracellular pathogens like
Escherichia coli can also be phagocytosed by immune cells like neu-
trophils (47). The subsequent Vγ9Vδ2 T cell response is strictly
dependent on the ability of the phagocytosed pathogens to pro-
duce HMBPP. A more recent study also demonstrated that after
T cell priming, these pathogen-harboring neutrophils develop an
antigen-presenting phenotype (48). These studies suggest that the
presence of exogenous pAgs, intracellularly, is critical forVγ9Vδ2 T
cell activation and function. Admittedly, exogenous pAgs can also
be secreted by some extracellular pathogens or immune cells like
neutrophils, and administration of soluble pAgs in the presence
of BTN3A-expressing antigen-presenting cells trigger Vγ9Vδ2 T
cell activation, as was demonstrated in early studies of these T
cells (24). It is unknown how these extracellular pAgs get inter-
nalized, giving that their negatively charged features render direct
membrane permeability unlikely. Possible mechanisms for pass-
ing through the plasma and endocytic membranes may include
specific membrane transporters or charge neutralization by ester
formation.
PHOSPHOANTIGEN STRUCTURE AND BIOACTIVITY
The variable chemical structures of pAgs relate directly to their
bioactivity. The pyrophosphate moiety is central since its strong
negative charge can make electrostatic contacts with the positively
charged binding pocket of the B30.2 domain. Indeed, monophos-
phate substituents have significantly reduced specific activity com-
pared with their pyrophosphate counterparts (49). On the other
hand, large chemical groups like AMP can be added without affect-
ing the bioactivity of pAgs (49) and, in fact, some natural pAgs are
nucleotidic conjugates (50, 51) that may be processed by specific
antigen-presenting cells. More intriguingly, it has been found that
hydrolysis of the pyrophosphate moiety is associated with pAg
bioactivity and non-hydrolyzable analogs of pAgs can even inhibit
the T cell activation (52). These features suggest that either pre- or
post-processing of pAgs can occur before or after association with
the B30.2 domain and may have important implications for T cell
activation.
Since the pyrophosphate moiety is essentially the same for every
pAg, the potency of pAgs is largely dependent on their organic
moieties. Changes in the length of the alkyl chain and positions
of the double bond, even though very subtle, can lead to dramatic
change in potency (49). Notably, the structural difference between
endogenous ligand IPP and exogenous HMBPP only lies in the
additional hydroxyl group on HMBPP, yet the potency and bind-
ing affinity of this strong ligand increases by about 1000-fold. One
possible explanation that was explored early on was the chemical
reactivity of pAgs. The polarizability of the C3 substituent cor-
relates with bioactivity: an increased specific activity for T cells
was observed upon addition of a halohydrin to the C3 position
(52). This leads to an interesting speculation that a covalent reac-
tion may occur between the pAg and its binding partner. More
recently, some studies have pointed out that the chirality of the
pAgs may also play a role in their bioactivity. It has been found
that E-stereoisomers are much more potent antigens for T cell
activation (53). Potential intramolecular hydrogen-bonding states
of these isomers affect the overall shape of the ligand and may be
important for binding to the B30.2 domain. Most of the studies
regarding the structure of pAgs were conducted before the identi-
fication of the B30.2 domain of BTN3A1 as the binding partner;
optimization of binding to this domain has already begun with
exciting implications for pAg-based therapeutics (35).
PHOSPHOANTIGENS SIGNAL THROUGH AN INSIDE-OUT
MECHANISM VIA THE B30.2 DOMAIN
Of course, the detection of pAgs intracellularly needs to trans-
late to a signal that can be detected by surveying Vγ9Vδ2 T
cells. We and others have proposed an inside-out signaling model
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FIGURE 8 | Model of the molecular changes that occur in BTN3A
molecules upon addition of 20.1 antibody or detection of accumulating
intracellular pAg. In this model, we propose that BTN3A molecules exist on
the surface of a healthy, unaffected cell in an inactive state, perhaps in a
conformation similar to the dimer 2 visualized in the crystal lattice (left). Upon
addition of the 20.1 antibody, dimer 2 is destabilized and BTN3A molecules
are converted/stabilized in the dimer 1 conformation. An increase in the
intracellular pAg concentration has a similar effect except the dimer
conversion is mediated by changes in the intracellular B30.2 domain, which
undergoes a conformational change upon pAg binding (hexagonal shape). This
conformational change induces structural reorganization of BTN3A molecules,
either via immobilization through B30.2 association with the actin
cytoskeleton or B30.2 multimerization of BTN3A molecules, which is then
signaled by an inside-out mechanism to change the architecture of the BTN3A
extracellular domains. This architectural change could alone be the signal that
Vγ9Vδ2 TCRs recognize, or recruitment of an additional, human-specific
accessory molecule (lime-green square) occurs, which directly engages the
Vγ9Vδ2 TCR.
(31, 33) whereby the binding of pAg intracellularly is translated
extracellularly for detection by the Vγ9Vδ2 TCR. This could be
through several means that work individually or in concert to ini-
tiate TCR recognition: (1) immobilization/clustering of BTN3A
that increases the avidity for the TCR, (2) a conformational
change of the BTN3A extracellular domains from non-stimulatory
(Dimer 2) to stimulatory (Dimer 1), or (3) the two previous
situations resulting in the recruitment of an additional factor
that directly engages the Vγ9Vδ2 TCR. Number 1 and 2 invoke
a direct interaction between Vγ9Vδ2 TCRs and the extracellu-
lar domains of BTN3A whereas version 3 involves an unknown
accessory protein that is the true Vγ9Vδ2 TCR ligand (Figure 8).
Whether BTN3A is directly recognized by the Vγ9Vδ2 TCR is
controversial; Vavassori and colleagues were able to measure an
interaction between the IgV domain of BTN3A1 and a Vγ9Vδ2
TCR used in their studies (32) while we have not be able to do
the same with the G115 Vγ9Vδ2 TCR and the full-length extra-
cellular domain of BTN3A1 (33). In addition, we have not been
able to stimulate Vγ9Vδ2 T cells with murine transfected BTN3A1
either through 20.1 antibody addition or through pAg treatment
(33) whereas others, using a different Vγ9Vδ2 TCR have observed
stimulation via 20.1 Ab treatment of BTN3A1 transfected Chinese-
hamster ovary (CHO) cells (54). pAg-mediated stimulation was
only observed in CHO cells containing human Chromosome
6. These conflicting results represent probably the most impor-
tant conundrum in the Vγ9Vδ2 T cell field at present. BTN3A
molecules are necessary but are they sufficient for Vγ9Vδ2 recog-
nition? Evidence for other molecules playing a role in Vγ9Vδ2
recognition and activation such as HSP-60 (55) and F1-ATPase
with or without ApoA1 (56) suggest this system could be a com-
plicated coordination of many molecular players. Further coor-
dination through adhesion molecules, activating and inhibitory
Natural Killer receptors, Toll-like receptors (TLRs), and Fc Recep-
tors [reviewed in Ref. (57)] also fine-tune Vγ9Vδ2 activation
thresholds and functional responses.
A feature of Vγ9Vδ2 TCRs that may be important in answering
the question regarding a direct interaction between the TCR and
BTN3A is that despite the fact that this population uniformly use a
Vγ9 and a Vδ2 chains in their TCR, there exists considerable diver-
sity within the Vγ-Jγ and Vδ-Dδ-Jδ rearrangement, which trans-
lates into significant amino acid diversity within the CDR3γ and
CDR3δ loops of these TCRs (58–60). These loops have been shown
via mutagenesis to be important for Vγ9Vδ2 T cell activation (60)
and sequence variation of these loops between T cell clones (con-
trolled for expression of Natural Killer receptors) translates into a
range of different, graded, reactivity (61). It is thus possible that
use of Vγ9Vδ2 TCRs with different sequences, and thus different
affinities for BTN3A, may be playing a role in the differing abilities
to measure interactions between the Vγ9Vδ2 TCR and BTN3A.
Alternatively there may be a requirement for additional co-factors
to be expressed on target cells in conjunction with BTN3A to fully
engage the majority of the Vγ9Vδ2 T cell repertoire.
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Clearly, we have just begun to pull the curtain back on the
inner-workings of Vγ9Vδ2 T cell ligand recognition and activa-
tion; identification of the B30.2 domain as the pAg sensor has
already resulted in compounds developed with higher potency
in vitro (35). Identification of additional players in this process
will lead to important therapeutic targets with implications both
for the treatment of tumors and microbial infections, but also for
minimizing immune-related side effects during the use of bispho-
sphonates for the treatment for osteoporosis and cancer-related
bone fractures.
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